ARD1 (EP357) Rabbit Monoclonal Antibody

Arrest-defect-1 protein (ARD1) is the catalytic subunit of NatA acetyltransferase responsible for N-terminal α-acetylation.  ARD1 is present in the cytoplasm and nucleus, and is also required for cellular proliferation.  In vitro studies demonstrated impaired cell proliferation in HepG2 hepatocellular carcinoma cells.  Its role in tumorigenesis is under debate.

ARD1 (EP357) Rabbit Monoclonal Antibody was reported to have both oncogenic and tumor suppressor function.  ARD1 acetylates β-catenin, promoting lung cancer proliferation.  Conversely, it was also shown to suppress tumor migration and invasion through acetylation of myosin light chain kinase.  Recent studies demonstrated upregulation of ARD1 in tumor tissue compared with matched normal tissues in colorectal and breast cancers.  However, the use of ARD1 as a prognostic marker is still controversial.  Studies reported ARD1 expression correlating with breast cancer progression and metastasis while another observed ARD1 association with better clinical outcome and fewer lymph node metastases in a different breast cancer cohort.  Further investigation will be required to clarify its prognostic potential.

Specifications

• Dilution Range: 1:100 – 1:200*